Orion Oyj
OMXH:ORNBV
Gross Margin
Orion Oyj
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| FI |
O
|
Orion Oyj
OMXH:ORNBV
|
7.6B EUR |
62%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
831.3B USD |
81%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
373.9B USD |
68%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
85%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
210.9B CHF |
74%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
189.1B CHF |
75%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
163.2B GBP |
82%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
210.3B USD |
79%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
68%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
116.7B EUR |
70%
|
Orion Oyj
Glance View
Orion Oyj, a stalwart in the pharmaceutical industry, has carved out a significant niche for itself since its inception in Finland. The company was founded in 1917, and over the years, it has evolved into a crucial player in the global medical landscape. As a fully integrated pharmaceutical entity, Orion’s operations encompass everything from research and development to manufacturing and distribution. Its primary areas of focus include the development of therapies for central nervous system disorders, oncology, and respiratory diseases, as well as a selection of veterinary medicines and active pharmaceutical ingredients (APIs). This comprehensive approach enables Orion to maintain control over the entire drug production pipeline, ensuring quality and innovation are at the forefront of its mission. Orion's business strategy revolves around a robust combination of proprietary innovations and strategic partnerships. The company invests heavily in R&D, dedicating a substantial portion of its revenue to discovering and developing new drugs. By doing so, it fortifies its product pipeline, ensuring a steady influx of new offerings that cater to unmet medical needs, fostering a competitive edge in the market. Additionally, Orion supplements its earnings through collaborations with other pharmaceutical giants, expanding its market reach and sharing resources to mitigate risks associated with the costly drug development process. Through this dual approach of in-house excellence and collaborative ventures, Orion Oyj effectively sustains its financial health, continually fueling its growth and ensuring it remains a formidable force in the international pharmaceutical arena.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Orion Oyj's most recent financial statements, the company has Gross Margin of 61.5%.
You don't have any saved screeners yet